Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

UnknownEarly Phase 1

NCT03993821

Burosumab for CSHS

Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fib…

United States1 participantsStarted 2019-07-01

Treatment: Burosumab